2-(4-Bromophenyl)-4-methylmorpholine | 83081-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-(4-Bromophenyl)-4-methylmorpholine
• CAS: 83081-06-5
• 化学式: C₁₁H₁₄BrNO
• 分子量: 256.142
• InChiKey: JXMXBBJTBHSOJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Bromophenyl)-4-methylmorpholine 在 盐酸 、 硫酸 作用下， 以 乙醇 、 苯 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Synthesis, Toxicological, and Pharmacological Assessment of Derivatives of 2-Aryl-4-(3-arylpropyl)morpholines

  摘要：

  The synthesis of nine original morpholine derivatives, i.e.2-aryl-4-(3-arylpropyl)morpholines, is described. The structure of all synthesised derivatives was proved by IR and H-1-NMR, and some C-13-NMR. Acute toxicity studies of the compounds of them by were performed on mice. A comparative pharmacological study of the in vivo effects on the central nervous system was undertaken using the screening tests: hexobarbital induced sleeping time; locomotor activity; and behaviour despair (for antidepressive activity). The most active compound 4-(2-benzoylethyl)-2-phenyl-3-methyl) morpholine 4e was studied for MAO-A and MAO-B inhibition in vitro in rat brain mitochondria preparations.

  DOI：

  10.1002/(sici)1521-4184(199811)331:11<342::aid-ardp342>3.0.co;2-6
• 作为产物：
  描述：

  在 甲酸 作用下， 反应 5.5h， 生成 2-(4-Bromophenyl)-4-methylmorpholine
  参考文献：
  名称：

  一种制备2,4-二取代吗啉的新方法

  摘要：

  在ω-acetoxyacetophenones（偶姻酯）的还原胺化1与仲氨基乙醇3和根据洛伊卡特-沃勒克反应，2-（芳基）甲酸，4-二取代的吗啉是5获得。讨论了反应的中间阶段。ω-卤代苯乙酮的反应类似。

  DOI：

  10.1002/cber.19821150726

文献信息

• [EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER AVEC LESDITS COMPOSÉS
  申请人：UNIV HEALTH NETWORK

  公开号：WO2013053051A1

  公开（公告）日：2013-04-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供了由结构式（I）或（I'）表示的吲唑化合物或其药用可接受的盐。还描述了这些药物组合物及其用作蛋白激酶抑制剂的方法，如对乳腺癌细胞、结肠癌细胞和卵巢癌细胞具有抗癌活性的TTK蛋白激酶、极化样激酶4（PLK4）和极化激酶。
• INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：University Health Network

  公开号：US20140371202A1

  公开（公告）日：2014-12-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供由结构式（I）或（I'）所代表的吲唑化合物或其药学上可接受的盐。还描述了制备药物组合物和使用方法，作为蛋白激酶抑制剂，例如TTK蛋白激酶，极化样激酶4（PLK4）和极化激酶，对乳腺癌细胞，结肠癌细胞和卵巢癌细胞具有抗癌活性。
• KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：UNIVERISTY HEALTH NETWORKS

  公开号：US20140051679A1

  公开（公告）日：2014-02-20

  The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

  本文提供了一种由结构式（I）表示的化合物，或其药学上可接受的盐。还描述了这些药物组合物的制备方法和使用方法。
• YORDANOVA, K.;SHVEDOV, V.;DANTCHEV, D., CHEM. BER., 1982, 115, N 7, 2635-2642
  作者：YORDANOVA, K.、SHVEDOV, V.、DANTCHEV, D.

  DOI：——

  日期：——
• STOEVA-JORDANOVA, K. P.;DANCHEV, D. K.;KARASAN, P. X.
  作者：STOEVA-JORDANOVA, K. P.、DANCHEV, D. K.、KARASAN, P. X.

  DOI：——

  日期：——